Kardigan Files IPO to Fund Cardiovascular Disease Therapies
Kardigan IPO filing marks a milestone in cardiovascular drug development, highlighting renewed investor interest in biotech innovations beyond oncology.
Kardigan IPO filing marks a milestone in cardiovascular drug development, highlighting renewed investor interest in biotech innovations beyond oncology.
Nvidia billionaire and board member Mark Stevens gifts $175 million to launch a new Bay Area medical school integrating AI and technology,…
FDA Commissioner Marty Makary’s resignation throws the agency into turmoil, threatening drug approvals and pressuring biotech and healthcare stocks.
FDA gridlock clouds drug approval timelines, pressuring healthcare stocks and ETFs like XLV and IBB.